Maidstone Hospital

The trials here

What the 26 trials at this site are about, from their registry records.

Conditions

• Childhood cancers5 trials
• Colorectal cancer5 trials
• Lung cancer4 trials
• Liver and biliary tract cancer3 trials
• Metastatic breast cancer3 trials
• Multiple myeloma3 trials
• Prostate cancer3 trials
• Acute myeloid leukaemia2 trials
• Macular degeneration2 trials
• Bladder cancer1 trial
• Chronic myeloid leukaemia1 trial
• Diabetic eye disease1 trial
• and 5 more

Phase

• Phase 317 trials
• Phase 22 trials

Status

• Active, not recruiting11 trials
• Completed7 trials
• Recruiting5 trials
• Not yet recruiting2 trials
• Terminated1 trial

Lead sponsor

• Hoffmann-La Roche4 trials
• Pfizer3 trials
• Amgen2 trials
• Imperial College London2 trials
• University College, London2 trials
• and 13 more

Running trials

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

  Contact: Riyaz Shah, MBBS, Ph.D. (principal investigator)

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Pfizer· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery

  NCT04103372· Imperial College London· Source

  Contact: Principal Investigator

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· UNICANCER· Source

  Contact: Justin WATERS, MD

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Recruiting

  Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

  NCT05655078· University College, London· Source

  Contact: Riyaz Shah

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT05160584· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

  NCT04546620· Phase 2· University Hospital Southampton NHS Foundation Trust· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  NCT03562169· Phase 3· University of Leeds· Source

  Contact: Lolita Banerjee

• Active, not recruiting

  Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

  NCT02804815· Phase 3· University College, London· Source

• Recruiting

  Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers

  NCT02222844· Imperial College London· Source

  Contact: Paulette Basham

• Active, not recruiting

  Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

  NCT02170090· Phase 3· Universitätsklinikum Hamburg-Eppendorf· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer3 recruiting
• Childhood cancers2 recruiting
• Lung cancer2 recruiting
• Liver and biliary tract cancer1 recruiting
• Mesothelioma1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Completed

  Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

  NCT05198934· Phase 3· Amgen· Source

• Completed

  Psychological Impact of COVID-19 on Intensive Care Survivors

  NCT05092529· Royal Liverpool University Hospital· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Takeda· Source

• Completed

  National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

  NCT02664935· Phase 2· University of Birmingham· Source

• Completed

  Stereotactic Radiotherapy for Wet AMD (STAR)

  NCT02243878· Phase 3· King's College Hospital NHS Trust· Source

• Completed

  Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

  NCT01726374· Phase 3· Institute of Cancer Research, United Kingdom· Source